Frontlight ResearchEarly access
Sickle cell disease trials in Kenya
5 of 5 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Where
- Ahero, Eldoret, Kisumu, Siaya
- Age
- 12 years to 100 years
- People
- 354 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06439082 - Phase 2Taking peopleA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- Where
- Kericho, Kisumu, Siaya
- Age
- 6 months to 18 years
- People
- 95 worldwide
- Run by
- Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00 - Phase 3Taking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Kericho, Kisumu, Nairobi, Siaya
- Age
- 2 years and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - Phase 3Not yet taking people in KenyaA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Eldoret, Kisumu, Nairobi, Siaya
- Age
- 12 years and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - Phase 2/3CompletedA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Kisumu, Nairobi
- Age
- 12 years to 64 years
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00